1. bookVolume 64 (2014): Edizione 2 (June 2014)
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
ISSN
1330-0075
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese
Accesso libero

Computational design of drug candidates for influenza A virus subtype H1N1 by inhibiting the viral neuraminidase-1 enzyme

Pubblicato online: 06 Jun 2014
Volume & Edizione: Volume 64 (2014) - Edizione 2 (June 2014)
Pagine: 157 - 172
Accettato: 14 Jan 2014
Dettagli della rivista
License
Formato
Rivista
eISSN
1846-9558
ISSN
1330-0075
Prima pubblicazione
28 Feb 2007
Frequenza di pubblicazione
4 volte all'anno
Lingue
Inglese

1. J. K. Taubenberger and D. M. Morens, 1918 Influenza: the mother of all pandemic, Emerg. Infect. Dis. 12 (2006) 15-22; DOI: 10.3201/eid1201.050979.10.3201/eid1201.050979329139816494711Search in Google Scholar

2. P. Auewarakul, O. Suptawiwat, A. Kongchanagul, C. Sangma, Y. Suzuki, K. Ungchusak, S. Louisirirotchanakul, H. Lerdsamran, P. Pooruk, A. Thitithanyanont, C. Pittayawonganon, C.-T. Guo, H. Hiramatsu, W. Jampangern, S. Chunsutthiwat and P. Puthavathana, An avian influenza H5N1 virus that binds to a human-type receptor, J. Virol. 81 (2007) 9950-9955; DOI: 10.1128/ JVI.00468-07.10.1128/JVI.00468-07204539817626098Search in Google Scholar

3. I. V. Alymova, A. Portner, V. P. Mishin, J. A. McCullers, P. Freiden and G. L. Taylor, Receptor- -binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein, Glycobiology 22 (2012) 174-180; DOI: 10.1093/glycob/cwr112.10.1093/glycob/cwr112325550521846691Search in Google Scholar

4. S.-Q. Wang, Q.-S. Du, R.-B. Huang, D.-W. Zhang and K.-C. Chou, Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus, Biochem. Biophys. Res. Commun. 386 (2009) 432-436; DOI: 10.1016/j.bbrc.2009.06.016.10.1016/j.bbrc.2009.06.01619523442Search in Google Scholar

5. H. T. Nguyen, T. G. Sheu, V. P. Mishin, A. I. Klimov and L. V Gubareva, Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays, Antimicrob. Agents Chemother. 54 (2010) 3671-3677; DOI: 10.1128/ AAC.00581-10.10.1128/AAC.00581-10293494920585136Search in Google Scholar

6. N. J. Dharan, L. V. Gubareva, J. J. Meyer, M. Okomo-Adhiambo, R. C. McClinton, S. A. Marshall, K. St George, S. Epperson, L. Brammer, A. I. Klimov, J. S. Bresee and A. M. Fry, Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States, JAMA 301 (2009) 1034-1041; DOI: 10.1001/jama.2009.294.10.1001/jama.2009.29419255110Search in Google Scholar

7. T. Kolomin, M. Shadrina, P. Slominsky, S. Limborska and N. Myasoedov, A new generation of drugs: Synthetic peptides based on natural regulatory peptides, Neurosci. Med. 4 (2013) 223-252; DOI: 10.4326/nm.2013.44035.Search in Google Scholar

8. C. D. Fjell, J. A. Hiss, R. E. W. Hancock and G. Schneider, Designing antimicrobial peptides: form follows function, Nat. Rev. Drug Discov. 11 (2012) 37-51; DOI: 10.1038/nrd3591.10.1038/nrd359122173434Search in Google Scholar

9. S. Riedl, D. Zweytick and K. Lohner, Membrane-active host defense peptides - challenges and perspectives for the development of novel anticancer drugs, Chem. Phys. Lipids 164 (2011) 766-781; DOI: 10.1016/j.chemphyslip.2011.09.004.10.1016/j.chemphyslip.2011.09.004322076621945565Search in Google Scholar

10. P. Vlieghe, V. Lisowski, J. Martinez and M. Khrestchatisky, Synthetic therapeutic peptides: science and market, Drug. Disc. Today 15 (2010) 40-56; DOI: 10.1016/j.drudis.2009.10.009.10.1016/j.drudis.2009.10.00919879957Search in Google Scholar

11. R. Benigni and C. Bossa, Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology, Mutat. Res. 659 (2008) 248-261; DOI: 10.1016/j.mrrev.2008.05.003.10.1016/j.mrrev.2008.05.00318621573Search in Google Scholar

12. U. S. F. Tambunan, N. Amri and A. A. Parikesit, In silico design of cyclic peptides as influenza virus, a subtype H1N1 neuraminidase inhibitor, African J. Biotechnol. 11 (2012) 11474-11491; DOI: 10.5897/AJB11.4094.10.5897/AJB11.4094Search in Google Scholar

13. C. A. Lipinski, F. Lombardo, B. W. Dominy and P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 46 (2001) 3-26.10.1016/S0169-409X(00)00129-0Search in Google Scholar

14. S.-L. Du, H. Pan, W.-Y. Lu, J. Wang, J. Wu and J.-Y. Wang, Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats, J. Pharmacol. Exp. Ther. 322 (2007) 560-568; DOI: 10.1124/jpet.107.122481.10.1124/jpet.107.12248117510318Search in Google Scholar

15. T. R. White, C. M. Renzelman, A. C. Rand, T. Rezai, C. M. McEwen, V. M. Gelev, R. A. Turner, R. G. Linington, S. S. F. Leung, A. S. Kalgutkar, J. N. Bauman, Y. Zhang, S. Liras, D. A. Price, A. M. Mathiowetz, M. P. Jacobson and R. S. Lokey, On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds, Nat. Chem. Biol. 7 (2011) 810-817; DOI: 10.1038/nchembio. 664.Search in Google Scholar

16. M. Brvar, A. Perdih, M. Renko, G. Anderluh, D. Turk and T. Solmajer, Structure-based discovery of substituted 4,5’-bithiazoles as novel DNA gyrase inhibitors, J. Med. Chem. 55 (2012) 6413-6426; DOI: 10.1021/jm300395d.10.1021/jm300395d22731783Search in Google Scholar

17. C. Liao, M. Sitzmann, A. Pugliese and M. C. Nicklaus, Software and resources for computational medicinal chemistry, Future Med. Chem. 3 (2011) 1057-1085; DOI: 10.4155/fmc.11.63.10.4155/fmc.11.63341332421707404Search in Google Scholar

18. D. L. Wheeler, T. Barrett, D. A. Benson, S. H. Bryant, K. Canese, V. Chetvernin, D. M. Church, M. DiCuccio, R. Edgar, S. Federhen, L. Y. Geer, Y. Kapustin, O. Khovayko, D. Landsman, D. J. Lipman, T. L. Madden, D. R. Maglott, J. Ostell, K. D. Pruitt, G. D. Schuler, L. M. Schriml, E. Sequeira, S. T. Sherry, K. Sirotkin, A. Souvorov, G. Starchenko, T. O. Suzek, R. Tatusov, T. A. Tatusova, L. Wagner and E. Yaschenko, Database resources of the National Center for Biotechnology Information, Nucl. Acids Res. 35 (2007) D5-D12; DOI: 10.1093/nar/gkl1031.10.1093/nar/gkl1031178111317170002Search in Google Scholar

19. U. S. F. Tambunan, R. Harganingtyas and A. A. Parikesit, In silico modification of (1R, 2R, 3R, 5S)-(-)-isopinocampheylamine as inhibitors of M2 proton channel in Influenza A virus subtype H1N1, using the molecular docking approach, Trends Bioinform. 5 (2012) 25-46; DOI: 10.3923/ tb.2012.25.46.10.3923/tb.2012.25.46Search in Google Scholar

20. U. S. F. Tambunan, N. Bramantya and A. A. Parikesit, In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC), BMC Bioinformatics 12 (Suppl. 13) (2011) S23-S38; DOI:10.1186/1471-2105-12-S13-S23.10.1186/1471-2105-12-S13-S23327884022373132Search in Google Scholar

21. R. Benigni and C. Bossa, Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology, Mutat. Res. 659 (2008) 248-261; DOI: 10.1016/j.mrrev.2008.05.003.10.1016/j.mrrev.2008.05.00318621573Search in Google Scholar

22. T. Sander, J. Freyss, M. von Korff, J. R. Reich and C. Rufener, OSIRIS, an entirely in-house developed drug discovery informatics system, J. Chem. Inf. Model. 49 (2009) 232-246; DOI: 10.1021/ ci800305f.10.1021/ci800305f19434825Search in Google Scholar

23. D. Lagorce, O. Sperandio, H. Galons, M. A. Miteva and B. O. Villoutreix, FAF-drugs2: free ADME/ tox filtering tool to assist drug discovery and chemical biology projects, BMC Bioinformatics 9 (2008) 396-405; DOI: 10.1186/1471-2105-9-396. 10.1186/1471-2105-9-396256105018816385Search in Google Scholar

24. A. D. MacKerell, N. Banavali and N. Foloppe, Development and current status of the CHARMM force field for nucleic acids, Biopolymers 56 (2000) 257-265; DOI: 10.1002/1097-0282 (2000)56:4< 257::AID-BIP10029>3.0.CO;2-W.Search in Google Scholar

25. Y. Shen, M. K. Gilson and B. Tidor, Charge optimization theory for induced-fit ligands, J. Chem. Theory Comput. 8 (2012) 4580-4592; DOI: 10.1021/ct200931c.10.1021/ct200931c349634623162383Search in Google Scholar

26. J. R. Williams, A. L. Khandoga, P. Goyal, J. I. Fells, D. H. Perygin, W. Siess, A. L. Parrill, G. Tigyi and Y. Fujiwara, Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation, J. Biol. Chem. 284 (2009) 17304-17319; DOI: 10.1074/jbc. M109.003194.10.1074/jbcSearch in Google Scholar

27. G. L. Warren, C. W. Andrews, A.-M. Capelli, B. Clarke, J. LaLonde, M. H. Lambert, M. Lindvall, N. Nevins, S. F. Semus, S. Senger, G. Tedesco, I. D. Wall, J. M. Woolven, C. E. Peishoff and M. S. Head, A critical assessment of docking programs and scoring functions, J. Med. Chem.49 (2006) 5912-5931; DOI: 10.1021/jm050362n.10.1021/jm050362n17004707Search in Google Scholar

28. Y. Modis, S. Ogata, D. Clements and S. C. Harrison, A ligand-binding pocket in the dengue virus envelope glycoprotein, Proc. Natl. Acad. Sci. USA 100 (2003) 6986-6991; DOI: 10.1073/pnas. 0832193100.10.1073/pnasSearch in Google Scholar

29. M. Takano, T. P. Terada and M. Sasai, Unidirectional Brownian motion observed in an in silico single molecule experiment of an actomyosin motor, Proc. Natl. Acad. Sci. USA 107 (2010) 7769-7774; DOI: 10.1073/pnas.0911830107.10.1073/pnas.0911830107286784720385833Search in Google Scholar

30. S. Rogers, R. Wells and M. Rechsteiner, Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis, Science 234 (1986) 364-368, DOI: 10.1126/science.2876518. 10.1126/science.28765182876518Search in Google Scholar

Articoli consigliati da Trend MD

Pianifica la tua conferenza remota con Sciendo